Sixteen novel cancer therapies were approved in the US in 2024. Surprisingly, they add an average of 3 months of incremental survival (vs 10-15 years lost) and benefit a median of just ~1600 patients.

My analysis of 2024 cancer approvals on Substack (7 mins): https://open.substack.com/pub/amodernproposal/p/too-little-for-too-few-the-average